Drug Trial Radar · NCT04840589
Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Suspended
Enrollment
66
Planned (sponsor's estimate)
Start
Feb 2, 2022
Primary completion
Sep 1, 2028
Study completion Sep 1, 2028
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Apr 12, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase I/Ib trial is to find out the best dose, possible benefits and/or side effects of BET bromodomain inhibitor ZEN-3694 (ZEN003694) when given in combination with nivolumab with or without ipilimumab in treating patients with solid tumors. ZEN003694 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving ZEN003694 in combination with nivolumab with or without ipilimumab may shrink or stabilize solid tumors.
Conditions
- Metastatic Malignant Solid Neoplasm
- Recurrent Malignant Solid Neoplasm
- Recurrent Platinum-Resistant Ovarian Carcinoma
- Refractory Ovarian Carcinoma
Interventions
BET Bromodomain Inhibitor ZEN-3694Drug
Given PO
Biopsy ProcedureProcedure
Undergo a biopsy
Biospecimen CollectionProcedure
Undergo blood sample collection
Computed TomographyProcedure
Undergo a CT scan
IpilimumabBiological
Given IV
Magnetic Resonance ImagingProcedure
Undergo MRI
NivolumabBiological
Given IV
Positron Emission TomographyProcedure
Undergo a PET scan
X-Ray ImagingProcedure
Undergo x-ray
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerabilityTime frame: Up to 1 cycle of treatment for doublet group (4 weeks) and up to 2 cycles for triplet group (6 weeks)
- Phase 2 recommended dose for the combined regimensTime frame: Up to 1 cycle of treatment for doublet group (4 weeks) and up to 2 cycles for triplet group (6 weeks)
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
National Cancer Institute Developmental Therapeutics Clinic
Bethesda, Maryland
National Institutes of Health Clinical Center
Bethesda, Maryland
Mount Sinai Hospital
New York, New York
Montefiore Medical Center-Einstein Campus
The Bronx, New York
Montefiore Medical Center-Weiler Hospital
The Bronx, New York
Montefiore Medical Center - Moses Campus
The Bronx, New York
Case Western Reserve University
Cleveland, Ohio
Oregon Health and Science University
Portland, Oregon
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.